The company remains entirely pre-revenue, with persistent R&D and SG&A expenses resulting in a net loss of $847,000 in 2024Q4.
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - |
| Cost of Goods Sold | 120K | 100K | 120K | 127K | 122K | 121K | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - |
| Gross Profit | -120K | -100K | -120K | -127K | -122K | -121K | 0 |
| Gross Margin % | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | 16.67% | 5.51% | -4.1% | -0.83% | - | - |
| Operating Expenses | 2.06K | 2.51M | 2.06M | 2.8M | 2.83M | 2.4M | 2.45M |
| OpEx % of Revenue | - | - | - | - | - | - | - |
| Selling, General & Admin | 1.13K | 1.78M | 1.13M | 1.73M | 1.54M | 845K | 931K |
| SG&A % of Revenue | - | - | - | - | - | - | - |
| Research & Development | 928 | 731K | 927K | 1.07M | 1.29M | 1.56M | 1.51M |
| R&D % of Revenue | - | - | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -2.06K | -2.61M | -2.06M | -2.8M | -2.83M | -2.4M | -2.45M |
| Operating Margin % | - | - | - | - | - | - | - |
| Operating Income Growth % | - | -26.8% | 26.49% | 1.13% | -17.68% | 1.72% | - |
| EBITDA | -1.94K | -2.51M | -1.94M | -2.67M | -2.71M | -2.28M | -2.34M |
| EBITDA Margin % | - | - | - | - | - | - | - |
| EBITDA Growth % | - | -29.49% | 27.49% | 1.33% | -18.58% | 2.31% | - |
| D&A (Non-Cash Add-back) | 120 | 100K | 120K | 127K | 123K | 122K | 110K |
| EBIT | -2.06K | -2.61M | -1.98M | -3.64M | -5.87M | -3.36M | -2.45M |
| Net Interest Income | -1.03K | -1.93M | -1.03M | -701K | -760K | -829K | -832K |
| Interest Income | 7K | 610K | 7K | 56K | 5K | 6K | 0 |
| Interest Expense | 1.04M | 2.54M | 1.03M | 757K | 765K | 835K | 832K |
| Other Income/Expense | -964 | -2.06M | -963K | -1.6M | -3.8M | -1.79M | 530K |
| Pretax Income | -3.02K | -4.67M | -3.02M | -4.4M | -6.63M | -4.2M | -1.92M |
| Pretax Margin % | - | - | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -3.02K | -4.67M | -3.02M | -4.4M | -6.63M | -4.2M | -1.92M |
| Net Margin % | - | - | - | - | - | - | - |
| Net Income Growth % | - | -54.72% | 31.39% | 33.63% | -57.93% | -119.1% | - |
| Net Income (Continuing) | -3.02K | -4.67M | -3.02M | -4.4M | -6.63M | -4.2M | -1.92M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.04 | -0.06 | -0.04 | -0.06 | -0.09 | -0.06 | -0.03 |
| EPS Growth % | - | -61.21% | 31.43% | 33.6% | -57.97% | -105.97% | - |
| EPS (Basic) | - | -0.06 | -0.04 | -0.06 | -0.09 | -0.06 | -0.03 |
| Diluted Shares Outstanding | 71.57K | 73.01M | 76.03M | 76.03M | 76.03M | 76.03M | 71.57M |
| Basic Shares Outstanding | 71.57K | 73.01M | 76.03M | 76.03M | 76.03M | 76.03M | 71.57M |
| Dividend Payout Ratio | - | - | - | - | - | - | - |
Imminent liquidity and dilution risk
As indicated by the company's financial statements, Jyong Biotech remains a pre-revenue entity, with zero top-line generation across the last five quarters, reflecting its current status as a clinical-stage firm entirely dependent on the successful regulatory progression of its botanical drug candidates like MCS-2.
The absence of revenue underscores the binary nature of the company's investment thesis, where value is derived solely from clinical milestones rather than commercial sales. Investors should monitor the transition from R&D-focused operations to potential commercialization, as the current lack of top-line growth necessitates reliance on external capital infusions.
Based on reported figures, the company's cost structure is dominated by persistent R&D and SG&A expenses, which have consistently resulted in quarterly operating losses, such as the $553,000 operating loss recorded in 2024Q4, highlighting the heavy financial burden of late-stage clinical trial execution.
The consistent quarterly burn rate suggests that management is maintaining a steady pace of clinical development despite the lack of revenue. This expense discipline is necessary for survival, yet it creates a structural dependency on continuous financing to cover the ongoing costs of patient enrollment and regulatory compliance.
According to recent SEC filings, the company's net income remains deeply negative, with a net loss of $847,000 in 2024Q4, a figure that reflects the absence of operational revenue and the high costs associated with advancing botanical drug candidates through the rigorous FDA regulatory pathway.
The lack of stock-based compensation suggests that management is not currently utilizing equity-based incentives to preserve cash, which is a prudent move given the liquidity constraints. However, the persistent net losses indicate that the company's valuation is entirely decoupled from traditional earnings metrics and remains tied to clinical trial outcomes.
As reported in financial statements, the company's extremely thin cash position of $1.178 million relative to its ongoing quarterly burn rate suggests a high probability of imminent dilutive financing, which may significantly impair existing shareholder value if the company fails to secure a strategic partnership.
The current cash runway appears insufficient to support the full duration of Phase III clinical trials, creating a precarious situation for investors. This liquidity risk warrants further investigation into the company's ability to access capital markets or secure non-dilutive funding, as the current financial profile suggests a potential going-concern risk.
Quick answers to the most common questions about buying MENS stock.
For fiscal year 2025, Jyong Biotech Ltd. Ordinary Shares (MENS) reported total revenue of $0.0M.
Jyong Biotech Ltd. Ordinary Shares (MENS) reported a net loss of $4.7M for the fiscal year ending 2025.